cloudy
The last COVID-19 candidate vaccine to begin human testing is the first in which volunteers will receive a painful injection. Instead, they’ll get a spray through their nose.
China on Wednesday approved the human phase 1 nasal spray vaccine, which has been jointly developed by researchers from Xiamen University and the University of Hong Kong, as well as vaccine maker Beijing Wantai Biological Pharmacy Enterprise Co.
Intranasal spray has already been developed as a flu vaccine and is for use in young people and adults who want to avoid further injections with needles that are not unusual. an option for muscle shocks for all types of vaccines.
The intranasal vaccine is the tenth Chinese candidate to take the level of human testing. The country is strengthening its leadership in vaccine progression after Western leader AstraZeneca PLC had to suspend its complex human trial to investigate spinal cord disease in a user who won their experimental vaccine. .
Intranasal spray is a weakened influenza virus that carries the genetic segments of the complex coronavirus protein. Administered through the nasal passages, it mimics herbal infection of respiratory viruses to stimulate the body’s immune reaction to the pathogen guilty of COVID-19, according to Science and Technology Daily, an article affiliated with China’s Ministry of Science and Technology.
Some scientists expect a nose-sprayed vaccine to have a better chance of preventing the spread of the insidious virus through the airways. to protect yourself from infection.
Preclinical studies have shown that the nasal vaccine can particularly damage the lungs in mice and hamsters when faced with coronavirus, Science and Technology Daily reported.
The nasal spray joins some 35 applicants who are lately being tested in humans as the global race intensifies to be the first with an effective vaccine against the fatal pathogen. Owned by China National Biotec Group Co. , they have focused on protecting their own vaccines.
CNBG stated that the two injections it was testing were effective in preventing infection. None of the Chinese diplomats and staff who visited the virus hot spots abroad reported infection several months after receiving the vaccines, Zhou Song, CNBG’s general counsel, said in an article published in Science and Technology Daily. CanSino, which uses a vaccine production strategy similar to that of AstraZeneca, said its military-backed injection is safe and has not caused any serious side effects testing.
Zhu Tao, co-founder and clinical director of CanSino, defended the vaccine against the allegation that it appears to cause fewer antibodies to those generated through competition such as AstraZeneca and Moderna Inc. The variation in antibody readings is the result of the use of other measurement methods, Zhu said in a presentation to investors this week.
Since the early stages of the COVID-19 crisis, the Japan Times has provided free access to very important data on the effect of the new coronavirus, as well as practical data on how to deal with the pandemic. today so that we can continue to provide you with up-to-date and detailed data on Japan.
The Japan Times LTD. All rights are reserved.